Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors.

Kaysia Ludford,Kanwal Pratap Singh Raghav,Mariela A. Blum Murphy,Nicole D. Fleming,Douglas A. Nelson,Michael Sangmin Lee,Brandon George Smaglo,Y. Nancy You,Matthew M. Tillman,Carlos Kamiya Matsuoka,Selvi Thirumurthi,Craig Messick,Benny Johnson,Eduardo Vilar-Sanchez,Arvind Dasari,Jane V Thomas,Wai Chin Foo,Wei Qiao,Scott Kopetz,Michael J. Overman

Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors.

2021

2520Background: Pembrolizumab (Pembro), anti-PD1 therapy, is FDA approved for refractory microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) advanced/metastatic solid tumors. T...

Keywords:

Cancer research
Refractory
locally advanced
Microsatellite instability
Medicine
Pembrolizumab
DNA mismatch repair

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations